Ovid Therapeutics (OVID) Stock Forecast & Price Target

Compare

1,666 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OVID Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Ovid

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OVID Stock 12 Month Forecast

Average Price Target

$4.43

▲(230.60% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. The average price target is $4.43 with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 230.60% change from the last price of $1.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,2.2,2.6,3,3.4000000000000004,3.8,4.2,4.6000000000000005,5,5.4,5.8,6.2,6.6000000000000005,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,2.002307692307692,2.2046153846153844,2.4069230769230767,2.609230769230769,2.8115384615384613,3.0138461538461536,3.216153846153846,3.418461538461538,3.6207692307692305,3.823076923076923,4.025384615384615,4.227692307692307,{"y":4.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.8,1.8153846153846154,1.8307692307692307,1.8461538461538463,1.8615384615384616,1.876923076923077,1.8923076923076922,1.9076923076923078,1.9230769230769231,1.9384615384615385,1.9538461538461538,1.9692307692307693,1.9846153846153847,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$7.00

Average Price Target$4.43

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

Buy

―

Reiterated

12/18/25

Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward

Thomas Shrader

BTIG

Buy

198.51%

Upside

Reiterated

12/18/25

Ovid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating

Boobalan Pachaiyappan

Roth MKM

Buy

123.88%

Upside

Initiated

12/11/25

Ovid Therapeutics (OVID) Gets a Buy from Roth MKM

Ram Selvaraju

H.C. Wainwright

$1.5→$2

Buy

49.25%

Upside

Reiterated

11/24/25

Ovid Therapeutics price target raised to $2 from $1.50 at H.C. WainwrightOvid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright

Marc Goodman

Leerink Partners

Buy

273.13%

Upside

Initiated

11/17/25

Ovid Therapeutics initiated with an Outperform at LeerinkOvid Therapeutics initiated with an Outperform at Leerink

Ritu Baral

TD Cowen

Buy

―

Reiterated

11/13/25

Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating

Jay Olson

Oppenheimer

Buy

422.39%

Upside

Reiterated

11/13/25

Oppenheimer Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)

Madison Elsaadi

B. Riley Securities

$3→$5

Buy

273.13%

Upside

Reiterated

10/09/25

B. Riley Securities Sticks to Their Buy Rating for Ovid Therapeutics (OVID)

Laura Chico

Wedbush

$3→$5

Buy

273.13%

Upside

Reiterated

10/03/25

Wedbush Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

Elemer Piros

Lucid Capital

$5.5

Buy

310.45%

Upside

Initiated

08/13/25

Ovid Therapeutics initiated with a Buy at Lucid CapitalOvid Therapeutics initiated with a Buy at Lucid Capital

Francois Brisebois

LifeSci Capital

Buy

198.51%

Upside

Upgraded

01/29/25

Ovid Therapeutics upgraded to Outperform from Perform at OppenheimerOvid Therapeutics upgraded to Outperform from Perform at Oppenheimer

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

Buy

―

Reiterated

12/18/25

Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward

Thomas Shrader

BTIG

Buy

198.51%

Upside

Reiterated

12/18/25

Ovid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating

Boobalan Pachaiyappan

Roth MKM

Buy

123.88%

Upside

Initiated

12/11/25

Ovid Therapeutics (OVID) Gets a Buy from Roth MKM

Ram Selvaraju

H.C. Wainwright

$1.5→$2

Buy

49.25%

Upside

Reiterated

11/24/25

Ovid Therapeutics price target raised to $2 from $1.50 at H.C. WainwrightOvid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright

Marc Goodman

Leerink Partners

Buy

273.13%

Upside

Initiated

11/17/25

Ovid Therapeutics initiated with an Outperform at LeerinkOvid Therapeutics initiated with an Outperform at Leerink

Ritu Baral

TD Cowen

Buy

―

Reiterated

11/13/25

Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating

Jay Olson

Oppenheimer

Buy

422.39%

Upside

Reiterated

11/13/25

Oppenheimer Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)

Madison Elsaadi

B. Riley Securities

$3→$5

Buy

273.13%

Upside

Reiterated

10/09/25

B. Riley Securities Sticks to Their Buy Rating for Ovid Therapeutics (OVID)

Laura Chico

Wedbush

$3→$5

Buy

273.13%

Upside

Reiterated

10/03/25

Wedbush Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

Elemer Piros

Lucid Capital

$5.5

Buy

310.45%

Upside

Initiated

08/13/25

Ovid Therapeutics initiated with a Buy at Lucid CapitalOvid Therapeutics initiated with a Buy at Lucid Capital

Francois Brisebois

LifeSci Capital

Buy

198.51%

Upside

Upgraded

01/29/25

Ovid Therapeutics upgraded to Outperform from Perform at OppenheimerOvid Therapeutics upgraded to Outperform from Perform at Oppenheimer

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ovid Therapeutics

1 Month

xxx

Success Rate

9/13 ratings generated profit

Average Return

+16.89%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +16.89% per trade.

3 Months

xxx

Success Rate

11/13 ratings generated profit

Average Return

+44.44%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 84.62% of your transactions generating a profit, with an average return of +44.44% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

5/6 ratings generated profit

Average Return

+208.55%

reiterated a buy rating 2 days ago

Copying Myles Minter's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +208.55% per trade.

2 Years

xxx

Success Rate

12/14 ratings generated profit

Average Return

+95.91%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +95.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OVID Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OVID has received 13 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. OVID average Analyst price target in the past 3 months is 4.43.

Each month's total comprises the sum of three months' worth of ratings.

OVID Financial Forecast

OVID Earnings Forecast

Next quarter’s earnings estimate for OVID is -$0.12 with a range of -$0.18 to -$0.06. The previous quarter’s EPS was -$0.17. OVID beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year OVID has Performed in-line its overall industry.

OVID Sales Forecast

Next quarter’s sales forecast for OVID is $81.00K with a range of $0.00 to $550.00K. The previous quarter’s sales results were $132.00K. OVID beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year OVID has Performed in-line its overall industry.

OVID Stock Forecast FAQ

What is OVID’s average 12-month price target, according to analysts?

Based on analyst ratings, Ovid Therapeutics Inc’s 12-month average price target is 4.43.

What is OVID’s upside potential, based on the analysts’ average price target?

Ovid Therapeutics Inc has 230.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OVID a Buy, Sell or Hold?

Ovid Therapeutics Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ovid Therapeutics Inc’s price target?

The average price target for Ovid Therapeutics Inc is 4.43. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $2.00. The average price target represents 230.60% Increase from the current price of $1.34.

What do analysts say about Ovid Therapeutics Inc?

Ovid Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of OVID?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ovid Therapeutics (OVID) Stock Forecast & Price Target

OVID Analyst Ratings

OVID Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ovid Therapeutics

OVID Analyst Recommendation Trends

OVID Financial Forecast

OVID Earnings Forecast

OVID Sales Forecast

OVID Stock Forecast FAQ

Detailed List of Analyst Forecasts